GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (HKSE:04332) » Definitions » Cyclically Adjusted Revenue per Share

Amgen (HKSE:04332) Cyclically Adjusted Revenue per Share : HK$297.62 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Amgen Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amgen's adjusted revenue per share for the three months ended in Mar. 2024 was HK$108.690. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is HK$297.62 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Amgen's average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amgen was 29.00% per year. The lowest was 9.80% per year. And the median was 14.50% per year.

As of today (2024-06-02), Amgen's current stock price is HK$1761.00. Amgen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was HK$297.62. Amgen's Cyclically Adjusted PS Ratio of today is 5.92.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 9.60. The lowest was 5.09. And the median was 7.31.


Amgen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Amgen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Cyclically Adjusted Revenue per Share Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.67 255.15 299.90 288.09 284.74

Amgen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 321.48 357.97 301.56 284.74 297.62

Competitive Comparison of Amgen's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PS Ratio falls into.



Amgen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=108.69/131.7762*131.7762
=108.690

Current CPI (Mar. 2024) = 131.7762.

Amgen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 52.283 100.560 68.513
201409 50.588 100.428 66.379
201412 53.476 99.070 71.130
201503 50.712 99.621 67.081
201506 54.209 100.684 70.949
201509 58.055 100.392 76.204
201512 56.236 99.792 74.260
201603 56.436 100.470 74.021
201606 58.400 101.688 75.680
201609 59.857 101.861 77.436
201612 62.372 101.863 80.688
201703 57.264 102.862 73.361
201706 61.394 103.349 78.281
201709 61.532 104.136 77.864
201712 62.438 104.011 79.105
201803 61.253 105.290 76.662
201806 72.039 106.317 89.290
201809 71.288 106.507 88.202
201812 75.998 105.998 94.480
201903 69.677 107.251 85.611
201906 75.322 108.070 91.845
201909 74.667 108.329 90.828
201912 81.013 108.420 98.465
202003 80.540 108.902 97.457
202006 81.245 108.767 98.432
202009 84.513 109.815 101.414
202012 88.058 109.897 105.590
202103 78.867 111.754 92.997
202106 87.939 114.631 101.092
202109 91.539 115.734 104.227
202112 94.667 117.630 106.052
202203 88.564 121.301 96.212
202206 96.369 125.017 101.579
202209 97.052 125.227 102.128
202212 98.967 125.222 104.147
202303 89.064 127.348 92.161
202306 101.902 128.729 104.314
202309 100.446 129.860 101.929
202312 118.976 129.419 121.143
202403 108.690 131.776 108.690

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Amgen  (HKSE:04332) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amgen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1761.00/297.62
=5.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 9.60. The lowest was 5.09. And the median was 7.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amgen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Amgen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (HKSE:04332) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (HKSE:04332) » Definitions » Cyclically Adjusted Revenue per Share
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (HKSE:04332) Headlines

No Headlines